Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients

Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients

Background:. Coronavirus disease 2019 (COVID-19) is a global pandemic that has caused more than 600 million cases and over six million deaths worldwide. Despite the availability of vaccination, COVID-19 cases continue to grow making pharmacological interventions essential. Remdesivir (RDV) is an FDA...

Full description

Bibliographic Details
Main Authors: Kaiyan Liu, Sydney Stern, Emily L. Heil, Linhao Li, Rula Khairi, Scott Heyward, Hongbing Wang
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2023-03-01
Series:Hepatology Communications
Online Access:http://journals.lww.com/10.1097/HC9.0000000000000034

Internet

http://journals.lww.com/10.1097/HC9.0000000000000034

Similar Items